Asia-Pacific’s medical technology sector is on track to hit $132 billion by 2030, driven by aging populations, rising chronic disease rates, and a shortage of healthcare workers across the region.
A new report from Bain & Company, titled Building Global Champions: The Asia-Pacific Region’s Next Medtech Wave, finds that the region is shifting from a low-cost manufacturing base into a genuine source of innovation. Kevin Chang, head of Bain’s Healthcare & Life Sciences practice in Greater China, said the area’s role was long defined by manufacturing, adaptation and execution, but it is now entering a different phase — one where it generates innovation rather than just absorbing it.
Despite that shift, few companies in the region have built global scale. The firm traced the problem to five structural gaps that hold medtech firms back.
Funding and talent gaps constrain global ambitions
On funding, seed and Series A rounds in Asia-Pacific totaled just $2.2 billion across 124 deals in 2025. Only 10% of buyout value in the region — roughly $2.3 billion — went to medtech. Most of that capital flowed into already-established platforms, not companies trying to move from innovation to commercial scale.
Asia-Pacific also faces a shortage of regulatory and clinical talent experienced in international trials, global regulatory pathways and quality systems.
Delayed global patent filings limit licensing opportunities and mergers and acquisitions.
Weak commercialisation infrastructure and limited access to key opinion leaders outside home markets make things worse, as does a lack of health-economic evidence needed to support adoption and revenue after approval.
It’s a familiar pattern in fast-growing tech markets: the early-stage pipeline looks promising, but the bridge to global commercialisation remains rickety. Other industries, like semiconductor design and biotech, have faced similar bottlenecks in the region before eventually breaking through.
National strengths vary across the region
Japan and Australia have led on product development over the past two decades, according to the report. China and India have moved beyond volume manufacturing, while South Korea has emerged as a credible engine for software-driven medtech. Singapore has built strength in clinical translation and productisation.
Executives from EDBI, J.P. Morgan, A*STAR and Enterprise Singapore framed the city-state as a hub that connects regional innovation to global capital, talent and clinical networks.
The report concludes that investments made over the next 24 months will determine the region’s role in the global medtech industry. If the structural gaps are addressed, Asia-Pacific could become a leading exporter of medical innovation by 2030.